**Name of Journal: *World Journal of Hepatology***

**ESPS Manuscript NO: 27269**

**Manuscript Type: Original Article**

***Basic Study***

**DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis**

Asada K *et al*. DNA methylation of angiotensin II receptor

**Kiyoshi Asada, Yosuke Aihara, Hiroaki Takaya, Ryuichi Noguchi, Tadashi Namisaki, Kei Moriya, Masakazu Uejima, Mitsuteru Kitade, Tsuyoshi Mashitani, Kosuke Takeda, Hideto Kawaratani, Yasushi Okura, Kosuke Kaji, Akitoshi Douhara, Yasuhiko Sawada, Norihisa Nishimura, Kenichiro Seki, Akira Mitoro, Junichi Yamao, Hitoshi Yoshiji**

**Kiyoshi Asada, Yosuke Aihara, Hiroaki Takaya, Ryuichi Noguchi, Tadashi Namisaki, Kei Moriya, Masakazu Uejima, Mitsuteru Kitade, Tsuyoshi Mashitani, Kosuke Takeda, Hideto Kawaratani, Yasushi Okura, Kosuke Kaji, Akitoshi Douhara, Yasuhiko Sawada, Norihisa Nishimura, Kenichiro Seki, Akira Mitoro, Junichi Yamao, Hitoshi Yoshiji,** Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan

**Author contributions:** Asada K performed the majority of experiments and analyzed the data; Aihara Y and Takaya H performed the molecular investigations; Noguchi R, Namisaki T, Moriya K, Uejima M, Kitade M, Mashitani T, Takeda K, Kawaratani H, Okura Y, Kaji K, Douhara A, Sawada Y, Nishimura N and Seki K participated in treatment of animals; Mitoro A, Yamao J and Yoshiji H designed and coordinated the research; Asada K, Kaji K and Yoshiji H wrote the paper.

**Institutional review board statement:** As for the file of Institutional review board statement, it is not applicable to my studybecause no human subjects were analyzed in my study.

**Institutional animal care and use committee statement:** This study was approved by the animal experimental ethical committee at the Nara Medical University (No. 9354).

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Kiyoshi Asada**, Research Scientist, Third Department of Internal Medicine, Nara Medical University, Kashihara, 840 Shijocho, Kashihara, Nara 634-8521, Japan. [kasada@naramed-u.ac.jp](mailto:kasada@naramed-u.ac.jp)

**Telephone:** +81-744-223051

**Fax:** +81-744-247122

**Received:** May 20, 2016

**Peer-review started:** May 21, 2016

**First decision:** July 4, 2016

**Revised:** July 8, 2016

**Accepted:** August 27, 2016

**Article in press:**

**Published online:**

# Abstract

***AIM***

To clarify whether *Agtr1a* methylation is involved in the development of nonalcoholic steatohepatitis (NASH)-related liver fibrosis in adult rats.

***MEHODS***

Acholine-deficient amino acid (CDAA) diet model was employed for methylation analysis of NASH-related liver fibrosis. *Agtr1a* methylation levels were measured in the livers of CDAA- and control choline-sufficient amino acid (CSAA)-fed rats for 8 and 12 wk using quantitative methylation-specific PCR. Hepatic stellate cells (HSCs) were isolated by collagenase digestion of the liver, followed by centrifugation of the crude cell suspension through a density gradient. *Agtr1a* methylation and its gene expression were also analyzed during the activation of HSCs.

***RESULTS***

The mean levels of *Agtr1a* methylation in the livers of CDAA-fed rats (11.5% and 18.6% at 8 and 12 wk, respectively) tended to be higher (*P* = 0.06 and 0.09, respectively) than those in the livers of CSAA-fed rats (2.1% and 5.3% at 8 and 12 weeks, respectively). *Agtr1a* was not methylated at all in quiescent HSCs, but was clearly methylated in activated HSCs (13.8%, *P* < 0.01). Interestingly, although *Agtr1a* was hypermethylated, the *Agtr1a* mRNA level increased up to 2.2-fold (*P* < 0.05) in activated HSCs compared with that in quiescent HSCs, suggesting that *Agtr1a* methylation did not silence its expression but instead had the potential to upregulate its expression. These findings indicate that *Agtr1a* methylation and its upregulation of gene expression are associated with the development of NASH-related liver fibrosis.

***CONCLUSION***

This is the first study to show that DNA methylation is potentially involved in the regulation of a RAS-related gene expression during liver fibrosis.

# Key words: Epigenetics; DNA methylation; Angiotensin II receptor; Liver fibrosis; Nonalcoholic steatohepatitis

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

# Core tip: We report the first study to show that *Agtr1a* methylation occurred during the development of nonalcoholic steatohepatitis-related liver fibrosis. Interestingly, *Agtr1a* gene expression was upregulated during liver fibrosis, although *Agtr1a* was methylated. This study demonstrates for the first time that RAS-related gene expression is regulated by DNA methylation during liver fibrosis. This finding raises expectations about the therapeutic application of demethylating agents for the treatment of liver fibrosis.

Asada K, Aihara Y, Takaya H, Noguchi R, Namisaki T, Moriya K, Uejima M, Kitade M, Mashitani T, Takeda K, Kawaratani H, Okura Y, Kaji K, Douhara A, Sawada Y, Nishimura N, Seki K, Seki A, Yamao J, Yoshiji H. DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis. *World J Hepatol* 2016; In press

# INTRODUCTION

Liver fibrosis is a characteristic feature of chronic liver disease regardless of the etiology. Cirrhosis is the terminal condition of chronic liver diseases, and hepatic failure due to liver cirrhosis is caused by progressive fibrosis that ultimately results in nodular regeneration with loss of function[1-3]. Considering that hepatocellular carcinoma (HCC) also develops from liver fibrosis, it is necessary to investigate the molecular mechanisms underlying liver fibrosis development to reduce the morbidity and mortality of chronic liver disease.

The renin–angiotensin system (RAS) is continually activated in patients with chronic liver diseases, such as cirrhosis[4]. Angiotensin II (AT-II), an octapeptide produced mainly *via* the enzymatic cleavage of angiotensin I by angiotensin I-converting enzyme, reportedly plays an important role in chronic liver disease progression. AT-II activates a series of signal transduction pathways in activated hepatic stellate cells (HSCs) by binding to the AT-II type 1 receptor (AT1-R)[5]. We previously reported that AT1-R blockers significantly attenuate experimental liver fibrosis development with the suppression of activated HSC proliferation[6-8]. However, the molecular mechanisms regulating RAS-related gene expression remain unelucidated.

Epigenetic alterations, including DNA methylation, are involved in the progression of liver fibrosis and HCC in human and animal studies [9-11]. Recently, Chen *et al*[12] reported that RAS-related genes, especially *Agtr1a* encoding rat AT1-R, are methylated in rats born to mothers fed a methyl donor-deficient diet during gestation and lactation. They showed that *Agtr1a* methylation can be a surrogate marker to predict susceptibility in developing nonalcoholic fatty liver disease (NAFLD) later in life. However, it is unclear whether *Agtr1a* methylation is associated with the development of nonalcoholic steatohepatitis (NASH)-related liver fibrosis.

Here we employed choline-deficient amino acid (CDAA)-fed rats to evaluate the importance of *Agtr1a* methylation in the development of NASH-related liver fibrosis. Our results demonstrate that *Agtr1a* methylation is potentially associated with liver fibrosis development and HSC activation.

# MATERIALS AND METHODS

## *Animal model of liver disease*

Six-week-old male Fisher 344 rats (CLEA Japan, Inc., Osaka, Japan) were housed in a room under a controlled temperature and a 12/12-h light-dark cycle. The animals were divided into the following four experimental groups: (1) choline-sufficient amino acid diet (CSAA) for 8 wk (*n* = 4); (2) CSAA for 12 wk (*n* = 11); (3) CDAA for 8 wk (*n* = 10); and (4) CDAA for 12 wk (*n* = 12). Initially, sample sizes for group (1)–(5) were 5, 12, 10, and 12, respectively, but two animals (one for CSAA-diet for 8 wk and the other for CSAA-diet for 12 wk) were dropped out because of entry in another experiment. All animal procedures were performed in accordance with standard protocols and following the standard recommendations for the appropriate care and use of laboratory animals. This study was approved by the animal experiment ethical committee at the Nara Medical University (protocol number: 9354).

## *Isolation and activation of HSCs*

HSCs were isolated by the collagenase digestion of the liver of a 6-week-old male Fisher 344 rat using a perfusion system, followed by the centrifugation of the crude cell suspension through a density gradient, as described previously[13]. Genomic DNA and total RNA were isolated from freshly isolated HSCs in a quiescent state. Thereafter, HSCs were activated in a culture on a plastic dish for 5 d.

## *Genomic DNA isolation, sodium bisulfite modification, and quantitative real-time methylation-specific PCR*

Genomic DNA was isolated using a DNeasy® Blood and Tissue Kit (Qiagen, Hilden, Germany). Fully methylated control DNA was prepared by methylating genomic DNA with *Sss*I methylase (New England Biolabs, Beverly, MA), and completely unmethylated control DNA was purchased from EpigenDx (Hopkinton, MA). Bisulfite modification was performed using an EZ DNA Methylation-Gold Kit (Zymo Research, Irvine, CA). *Agtr1a* genomic structure is illustrated in Figure 1. An aliquot of 1 μl was used for quantitative real-time methylation-specific PCR (qMSP) with primers specific to a methylated sequence of *Agtr1a* (forward 5′-GGT TGG AAT TTG TAG AGT AGC GAC-3′, reverse 5′-CAA CGC TAA TAC CGA CCT CG-3′) and to a B2 repeat sequence, regardless of the methylation status, as demonstrated in a previous report[14].

qMSP was performed by real-time PCR using a Power SYBR® Green PCR Master Mix (Thermo Fisher Scientific, Waltham, MA) and a StepOnePlusTM Real-Time PCR® (Thermo Fisher Scientific, Waltham, MA). The methylation level was calculated as the methylation percentage obtained as follows: [(number of DNA molecules methylated at a target CpG island (CGI) in a sample)/(number of B2 repeats in the sample)]/[(number of DNA molecules methylated at the target CGI in completely methylated control DNA)/(number of B2 repeats in the completely methylated control DNA)] × 100, as described previously[15].

## *Quantitative real-time reverse transcription PCR*

Total RNA was extracted using an RNeasy® Mini Kit (Qiagen, Hilden, Germany). cDNA was synthesized from 1 μg of total RNA using a High Capacity RNA to cDNA Master Mix (Thermo Fisher Scientific, Waltham, MA). *Agtr1a* mRNA level was measured by quantitative PCR using the StepOnePlusTM Real-Time PCR® (Thermo Fisher Scientific, Waltham, MA). Primer sequences for *Agtr1a* and for *Ppia* were reported previously[14,16]. The number of *Agtr1a* cDNA molecules was normalized to that of *Ppia* cDNA molecules.

## *Statistical analysis*

The difference in mean methylation levels was analyzed using Welch’s *t-*test. The results were considered significant with a *P* value of < 0.05.

## RESULTS

## *Agtr1a methylation in the livers of CDAA-fed rats and activated HSCs*

To evaluate the status of *Agtr1a* methylation in the whole liver, we performed qMSP using the liver samples of CSAA- and CDAA-fed rats after the two feeding periods, 8 and 12 wk. The mean levels of *Agtr1a* methylation in the livers of CDAA-fed rats were 11.5% and 18.6% at 8 and 12 wk, respectively, whereas those in the livers of CSAA-fed rats were 2.1% and 5.3% at 8 and 12 wk, respectively. These findings suggested that the levels of *Agtr1a* methylation in the livers of CDAA-fed rats tended to be higher than those in the livers of CSAA-fed rats at 8 and 12 weeks (*P* = 0.06 and 0.09, respectively; Figure 2).

Next, we evaluated the level of *Agtr1a* methylation during HSC activation *in vitro*. We found that *Agtr1a* methylation was not detected at all in quiescent HSCs, but was clearly observed in activated HSCs (13.8%, *P* < 0.01; Figure 3). Taken together with the *in vivo* results, our findings indicate that *Agtr1a* is hypermethylated in accordance with the development of NASH-related liver fibrosis.

## *Agtr1a expression in activated HSCs, and its association with methylation*

To address the contribution of *Agtr1a* methylation to its gene expression, we performed quantitative real-time reverse transcription PCR using quiescent and activated HSCs. *Agtr1a* expression was observed in quiescent HSCs in which *Agtr1a* was unmethylated. Unexpectedly, *Agtr1a* expression increased up to 2.2-fold (*P* < 0.05) in the activated HSCs compared with that in quiescent HSCs, although *Agtr1a* was methylated (Figure 4). Interestingly, in contrast to the general relationship between promoter CGIs and gene expression, *Agtr1a* methylation did not silence its expression but instead had the potential to upregulate its expression.

# DISUCUSSION

In this study, we found that *Agtr1a* methylation occurred during the development of NASH-related liver fibrosis. *Agtr1a*, whichencodes rat AT1-R, the receptor for AT-II, is an important factor in liver fibrosis development[17,18]. Our previous reports demonstrated that both AT-II and AT1-R gene expressions were upregulated during fibrosis development in rat liver, and the blockage of AT-II/AT1-R signaling could attenuate liver fibrosis[6-8]. Considering that *Agtr1a* methylation upregulates its gene expression, *Agtr1a* demethylation can suppress liver fibrosis.

*Agtr1a* methylation was first demonstrated in the liver of rats born to mothers fed a methyl donor-deficient diet during gestation and lactation, and it was reported that rat pups with *Agtr1a* methylation have a high risk of developing NAFLD[12]. Epigenetics derived from mother–pup interaction is a prominent research field, and epigenetic susceptibility to phenotypes and diseases, such as yellow coat color, stress response, and breast cancer in offspring, has been identified[19-21]. However, few studies have focused on whether these epigenetic changes responsible for susceptibility to particular diseases occur when the diseases actually develop in adults. Here we found that *Agtr1a* methylation, associated with susceptibility to NAFLD in pups, occurs in liver fibrosis development in adult NASH model rats.

As an experimental NASH model, we employed the CDAA model in this study. In the CDAA model, liver fibrosis develops at 8 weeks and severely progresses at 12 wk[22,23]. This model has an advantage of histological progression of liver fibrosis, which is very similar to human NASH. However, there are critical disadvantages of this model. For examples, obesity, glucose intolerance, and insulin resistance, which are common features in human NASH, are not observed in this model. It remains to be elucidated whether *Agtr1a* methylation is induced in other experimental NASH models.

In CDAA model, *Agtr1a* methylation in the livers of CDAA-fed rats tended to be higher than that in the livers of CSAA-fed rats, but it was not statistically significant. We consider that methylation levels are highly variable in each diet group and the difference between CDAA- and CSAA-fed rats appears to be small. This variability depends on individual differences in rats and tissue heterogeneity in each sample, but both of them are hardly avoided. On the other hand, in HSC analysis, *Agtr1a* methylation and upregulation was clearly observed. Even in the CDAA model, it would be better to isolate HSC from the livers of CDAA-fed rats to obtain clear methylation changes.

*Agtr1a* hypermethylation was associated with *Agtr1a* upregulation. As for the promoter CGI, hypermethylation is generally considered to be strongly associated with gene silencing[24]. On the other hand, in the case of a CGI at the gene body, hypermethylation occasionally contributes to overexpression [25]. In the *Agtr1a* gene, 5′-CGI was not located at the promoter region but was just downstream of the transcription initiation site (Figure 1), which might contribute to gene overexpression. It is hoped that the mechanism by which gene body methylation induces overexpression can be demonstrated.

In conclusion, this study demonstrates for the first time that RAS-related gene expression is regulated by DNA methylation during liver fibrosis. This finding raises expectations about the therapeutic application of demethylating agents for the treatment of liver fibrosis.

# COMMENTS

***Background***

The renin–angiotensin system (RAS) plays a crucial role in the development of liver fibrosis. Among the RAS-related genes, the methylation of *Agtr1a*, the rat Angiotensin II type 1 receptor gene, is a potential risk marker for the development of nonalcoholic fatty liver disease in rat pups. However, it remains to be elucidated whether *Agtr1a* methylation occurs in liver fibrosis development in adult rats with nonalcoholic steatohepatitis (NASH).

***Research frontiers***

Epigenetics derived from mother–pup interaction is a prominent research field. However, few studies have focused on whether these epigenetic changes responsible for susceptibility to particular diseases occur when the diseases actually develop in adults.

***Innovations and breakthroughs***

This study demonstrates for the first time that the expression of *Agtr1a*, a RAS-related gene, is regulated by DNA methylation during liver fibrosis.

***Applications***

The authors finding raises expectations about the therapeutic application of demethylating agents for the treatment of liver fibrosis.

***Terminology***

Epigenetics refers to heritable marks regulating tissue-specific gene expression without changes in the DNA sequence. Prominent epigenetic marks consist of DNA methylation and histone modifications. Aberrant epigenetic changes are involved in various diseases, including cancer.

***Peer-review***

This manuscript addresses the role of DNA methylation of angiotensin II receptor in fibrosis development in a rat model of NASH. The study is original and well designed.

# REFERENCES

1 **Albanis E**, Friedman SL. Hepatic fibrosis. Pathogenesis and principles of therapy. *Clin Liver Dis* 2001; **5**: 315-34, v-vi [PMID: 11385966 DOI: 10.1016/S1089-3261(05)70168-9]

2 **Olaso E**, Friedman SL. Molecular regulation of hepatic fibrogenesis. *J Hepatol* 1998; **29**: 836-847 [PMID: 9833926 DOI: 10.1016/S0168-8278(98)80269-9]

3 **Friedman SL**. Liver fibrosis -- from bench to bedside. *J Hepatol* 2003; **38** Suppl 1: S38-S53 [PMID: 12591185 DOI: 10.1016/S0168-8278(02)00429-4]

4 **Helmy A**, Jalan R, Newby DE, Hayes PC, Webb DJ. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. *Gastroenterology* 2000; **118**: 565-572 [PMID: 10702208 DOI: 10.1016/S0016-5085(00)70263-0]

5 **Bataller R**, Ginès P, Nicolás JM, Görbig MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V, Rodés J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. *Gastroenterology* 2000; **118**: 1149-1156 [PMID: 10833490]

6 **Yoshiji H**, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. *Hepatology* 2001; **34**: 745-750 [PMID: 11584371 DOI: 10.1053/jhep.2001.28231]

7 **Yoshiji H**, Kuriyama S, Fukui H. Blockade of renin-angiotensin system in antifibrotic therapy. *J Gastroenterol Hepatol* 2007; **22** Suppl 1: S93-S95 [PMID: 17567477 DOI: 10.1111/j.1440-1746.2006.04663.x]

8 **Yoshiji H**, Noguchi R, Ikenaka Y, Namisaki T, Kitade M, Kaji K, Shirai Y, Yoshii J, Yanase K, Yamazaki M, Tsujimoto T, Kawaratani H, Akahane T, Aihara Y, Fukui H. Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. *BMC Res Notes* 2009; **2**: 70 [PMID: 19416517 DOI: 10.1186/1756-0500-2-70]

9 **Kondo Y**, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis--A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. *Hepatology* 2000; **32**: 970-979 [PMID: 11050047 DOI: 10.1053/jhep.2000.19797]

10 **Arai E**, Ushijima S, Gotoh M, Ojima H, Kosuge T, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y. Genome-wide DNA methylation profiles in liver tissue at the precancerous stage and in hepatocellular carcinoma. *Int J Cancer* 2009; **125**: 2854-2862 [PMID: 19569176 DOI: 10.1002/ijc.24708]

11 **Asada K**, Kotake Y, Asada R, Saunders D, Broyles RH, Towner RA, Fukui H, Floyd RA. LINE-1 hypomethylation in a choline-deficiency-induced liver cancer in rats: dependence on feeding period. *J Biomed Biotechnol* 2006; **2006**: 17142 [PMID: 16877811 DOI: 10.1155/JBB/2006/17142]

12 **Chen G**, Broséus J, Hergalant S, Donnart A, Chevalier C, Bolaños-Jiménez F, Guéant JL, Houlgatte R. Identification of master genes involved in liver key functions through transcriptomics and epigenomics of methyl donor deficiency in rat: relevance to nonalcoholic liver disease. *Mol Nutr Food Res* 2015; **59**: 293-302 [PMID: 25380481 DOI: 10.1002/mnfr.201400483]

13 **Yoshiji H**, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Yanase K, Namisaki T, Imazu H, Fukui H. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. *Hepatology* 2002; **36**: 850-860 [PMID: 12297832 DOI: 10.1053/jhep.2002.35625]

14 **Hattori N**, Okochi-Takada E, Kikuyama M, Wakabayashi M, Yamashita S, Ushijima T. Methylation silencing of angiopoietin-like 4 in rat and human mammary carcinomas. *Cancer Sci* 2011; **102**: 1337-1343 [PMID: 21489049 DOI: 10.1111/j.1349-7006.2011.01955.x]

15 **Niwa T**, Tsukamoto T, Toyoda T, Mori A, Tanaka H, Maekita T, Ichinose M, Tatematsu M, Ushijima T. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. *Cancer Res* 2010; **70**: 1430-1440 [PMID: 20124475 DOI: 10.1158/0008-5472.CAN-09-2755]

16 **Vaswani K**, Chan HW, Verma P, Dekker Nitert M, Peiris HN, Wood-Bradley RJ, Armitage JA, Rice GE, Mitchell MD. The rat placental renin-angiotensin system - a gestational gene expression study. *Reprod Biol Endocrinol* 2015; **13**: 89 [PMID: 26260700 DOI: 10.1186/s12958-015-0088-y]

17 **Granzow M**, Schierwagen R, Klein S, Kowallick B, Huss S, Linhart M, Mazar IG, Görtzen J, Vogt A, Schildberg FA, Gonzalez-Carmona MA, Wojtalla A, Krämer B, Nattermann J, Siegmund SV, Werner N, Fürst DO, Laleman W, Knolle P, Shah VH, Sauerbruch T, Trebicka J. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. *Hepatology* 2014; **60**: 334-348 [PMID: 24619965 DOI: 10.1002/hep.27117]

18 **Rong X**, Li Y, Ebihara K, Zhao M, Naowaboot J, Kusakabe T, Kuwahara K, Murray M, Nakao K. Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. *Diabetologia* 2010; **53**: 1727-1731 [PMID: 20390403 DOI: 10.1007/s00125-010-1744-6]

19 **Waterland RA**, Jirtle RL. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. *Mol Cell Biol* 2003; **23**: 5293-5300 [PMID: 12861015]

20 **Weaver IC**, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, Dymov S, Szyf M, Meaney MJ. Epigenetic programming by maternal behavior. *Nat Neurosci* 2004; **7**: 847-854 [PMID: 15220929 DOI: 10.1038/nn1276]

21 **Govindarajah V**, Leung YK, Ying J, Gear R, Bornschein RL, Medvedovic M, Ho SM. In utero exposure of rats to high-fat diets perturbs gene expression profiles and cancer susceptibility of prepubertal mammary glands. *J Nutr Biochem* 2016; **29**: 73-82 [PMID: 26895667 DOI: 10.1016/j.jnutbio.2015.11.003]

22 **Douhara A**, Moriya K, Yoshiji H, Noguchi R, Namisaki T, Kitade M, Kaji K, Aihara Y, Nishimura N, Takeda K, Okura Y, Kawaratani H, Fukui H. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. *Mol Med Rep* 2015; **11**: 1693-1700 [PMID: 25421042 DOI: 10.3892/mmr.2014.2995]

23 **Aihara Y**, Yoshiji H, Noguchi R, Kaji K, Namisaki T, Shirai Y, Douhara A, Moriya K, Kawaratani H, Fukui H. Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model. *Hepatol Res* 2013; **43**: 1241-1250 [PMID: 23448275 DOI: 10.1111/hepr.12081]

24 **Deaton AM**, Bird A. CpG islands and the regulation of transcription. *Genes Dev* 2011; **25**: 1010-1022 [PMID: 21576262 DOI: 10.1101/gad.2037511]

25 **Kulis M**, Queirós AC, Beekman R, Martín-Subero JI. Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. *Biochim Biophys Acta* 2013; **1829**: 1161-1174 [PMID: 23938249 DOI: 10.1016/j.bbagrm.2013.08.001]

**P-Reviewer:** Bridle KR, Hamidi C, Safer AM **S-Editor:** Qi Y

**L-Editor: E-Editor:**

# 

# Figure 1 *Agtr1a* genomic structure. Each vertical tick on the top line shows an individual CpG site. GenBank accession number is listed at the left end on the bottom line. Open box shows exon 1, and dashed lines show the ambiguous boundary region of exon 1. qMSP was performed in the region marked with closed arrowheads.

# 

# Figure 2 Levels of *Agtr1a* methylation in the livers of control choline-sufficient amino acid - and choline-deficient amino acid -fed rats. The livers of choline-deficient amino acid (CDAA)-fed rats show higher *Agtr1a* methylation than that shown by the livers of choline-sufficient amino acid (CSAA)-fed rats at 8 (mean, 11.5% and 2.1%, *P* = 0.06) and 12 wk (mean, 18.6% and 5.3%, *P* = 0.09), respectively.

****

# Figure 3 Levels of *Agtr1a* methylation in the quiescent and activated hepatic stellate cells. *Agtr1a* is not methylated at all in quiescent hepatic stellate cells (HSCs) but hypermethylated (13.8%, *P* < 0.01) in activated HSCs. Data are presented as the mean ± SE.

****

# Figure 4 Relative *Agtr1a* expression normalized to *Ppia* in quiescent and activated hepatic stellate cells. Activated hepatic stellate cells (HSCs) show 2.2-fold higher (*P* < 0.05) *Agtr1a* expression than that shown by quiescent HSCs. Data are presented as the mean ± SE.